IP Library Granted Patent US 8,183,208
Granted Patent B2
US 8,183,208 · App. 11/968,904 · Granted May 22, 2012

Targeted delivery of drugs for the treatment of viral infections

Assignee: Faulk Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,183,208
App. No.
11/968,904
Granted
May 22, 2012
Kind
B2
Abstract

Conjugates of transferrin or transcobalamin with anti-viral agents are useful in the treatment of viral infections. Suitable anti-viral agents include apoptosis inducing compounds, compounds which inhibit the replication of the virus, a cytotoxic antibiotic, an alkylating agent, a plant toxin, and a bacterial mutant toxin. Transferrin or transcobalamin is preferably coupled to the anti-viral agent by means of glutaraldehyde.

Claims (9)

1. A method for inducing apoptosis in a cell infected with a virus, comprising

administering to said cell an effective amount of a conjugate containing transferrin and doxorubicin and wherein said transferrin and said anti-viral drug are linked via a glutaraldehyde linker, and wherein said conjugate induces apoptosis of said cell infected with a virus.

2. The method according to claim 1 , wherein said virus is selected from the group consisting of human immunodeficiency virus, cytomegalovirus, and hepatitis virus.

3. The method according to claim 2 , wherein said virus is human immunodeficiency virus.

4. A method for inducing apoptosis in a patient infected with a virus, comprising administering to a cell infected with a virus in said patient, a conjugate containing a targeting agent and an anti-viral agent, wherein said anti-viral agent is doxorubicin, said targeting agent is transferrin, and wherein said targeting agent and said anti-viral agent are linked via a glutaraldehyde linker, and wherein said conjugate induces apoptosis of said cell infected with a virus.

5. The method according to claim 4 , further comprising administering iron bound transferrin prior to administering said conjugate.

6. The method according to claim 4 , wherein said virus is selected from the group consisting of human immunodeficiency virus, cytomegalovirus, and hepatitis virus.

7. The method according to claim 6 , wherein said virus is human immunodeficiency virus.

8. The method according to claim 4 , further comprising administering a nonconjugated antiviral agent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2018
From: FAULK PHARMACEUTICALS, INC.
To: REDOX THERAPEUTICS, LLC
Reel/Frame 047295/0577 →
Continuity (4)
Continuation 10477997
Provisional Application 60290668 · May 15, 2001
Provisional Application 60355394 · Feb 8, 2002
Related Publication 20080103094A1 · May 1, 2008